{Disarmed} RE: {Disarmed} Report Raises New Concerns About Antidepressants-Suicide Link

[Guest guest]

....said report author Dr. Healy, a professor of psychiatry in the North Wales Department of Psychological Medicine at Cardiff University in Bangor, Wales. Healy, who described SSRIs as an "awfully useful group of drugs,"

MKULTRA

http://tinyurl.com/jz48p Pre-emptive treatment in Lilly study stirs debate - May 1, 2006

http://tinyurl.com/lf8wu The behavior modification plan of the MKULTRA Violence Control Centers included: (click: Reagan Era - Violence Center)

http://tinyurl.com/2ozo3 June 19, 2004 Bush plans to screen whole US population for mental illness ...Olanzapine (trade name Zyprexa), one of the atypical antipsychotic drugs recommended as a first line drug in the Texas algorithm, grossed $4.28bn (£2.35bn; 3.56bn) worldwide in 2003 and is Eli Lilly's top selling drug. A 2003 New York Times article by Gardiner reported that 70% of olanzapine sales are paid for by government agencies, such as Medicare and Medicaid.

Eli Lilly and MKUTLRA and LSD http://zmagsite.zmag.org/May2004/levine0504.html There is one Eli Lilly piece of history so bizarre that if told to many psychiatrists, one just might get diagnosed as paranoid schizophrenic and medicated with Zyrprexa. Former State Department officer Marks in The Search for the “Manchurian Candidate”: The CIA and Mind Control, The Secret History of the Behavioral Sciences (1979)—along with the Washington Post (1985) and the New York Times (1988)—reported an amazing story about the CIA and psychiatry. A lead player was psychiatrist D. Ewen Cameron, president of the American Psychiatric Association in 1953. Cameron was curious to discover more powerful ways to break down patient resistance. Using electroshock, LSD, and sensory deprivation, he was able to produce severe delirium. Patients often lost their sense of identity, forgetting their own names and even how to eat. The CIA, eager to learn more about Cameron’s brainwashing techniques, funded him under a project code-named MKULTRA. According to Marks, Cameron was part of a small army of the CIA’s LSD-experimenting psychiatrists. Where did the CIA get its LSD? Marks reports that the CIA had been previously supplied by the Swiss pharmaceutical corporation Sandoz, but was uncomfortable relying on a foreign company and so, in 1953, the CIA asked Eli Lilly to make them up a batch of LSD, which Lilly subsequently donated to the CIA.

Eli Lilly and MKULTRA and LSD and Serotonin http://tinyurl.com/nkha6 (search Eli Lilly) http://tinyurl.com/gw2m2 Lysergic acid is a metabolite of LSD, a hallucinogenic drug. Lysergic acid and similar compounds, collectively known as serotonin antagonists, bond to the same D-receptors used by serotonin. Through this action, lysergic acid blocks serotonin and redirects neural pulses.

Eli Lilly and Thimerosal and Serotonin http://tinyurl.com/jrqaq http://tinyurl.com/zmze4 In platelets, thimerosal causes aggregation, increase of arachidonic acid metabolism, and exocytotic release of serotonin. http://tinyurl.com/qgf8y Thimerosal induces a release reaction, seen in ultrastructural study and revealed by measurement of 14C-serotonin release. http://tinyurl.com/hw4e7 Autism and its Connection with the Neurotransmitter Serotonin.

Eli Lilly and Prozac and Serotonin http://www.prozac.com/index.jsp http://tinyurl.com/foglu PROZAC may help to correct this imbalance by increasing the brain's own supply of serotonin.

Eli Lilly and Zyprexa and Serotonin http://www.zyprexa.com/index.jsp http://tinyurl.com/hc9w4 Zyprexa, like the other atypical antipsychotics, appears to work by by blocking certain serotonin and dopamine receptors. Unlike some other medications it blocks the serotonin receptors more potently than the dopamine receptors. http://tinyurl.com/2ozo3

Eli Lilly and Strettera and Norepinephrine http://www.strattera.com/index.jsp http://tinyurl.com/kssty Strattera very selectively affects only the norepinephrine pathways. It does not influence the function of other neurotransmitters.

Eli Lilly and Cymbalta and Serotonin and Norepinephrine http://www.depressionhurts.com/index.jsp http://tinyurl.com/jsm7e Duloxetine (Cymbalta) is a new drug that is structurally related to the SSRIs and has been shown in clinical trials to be an effective treatment for depression. Cymbalta is classified as a selective serotonin and norepinephrine reuptake inhibitors ("SNRI").

H.W. Bush

1976-1977 Director of the Central Intelligence Agency (CIA)

1977-1979 Eli Lilly Corporate Director, appointed by the father of the future Vice President Dan Quayle who owned controlling interest in the corporation.

1981-1989 Vice-President H.W. Bush under President Reagan

1981-1989 Director or President Reagan’s "Drug Task Force"

1989-1993 President H.W. Bush and Vice-President Danforth (Dan) Quayle??

2001-2008 H.W. Bush’s son becomes President W. Bush with Vice-President (Dick) Cheney

This particular CIA partner certainly has a consistent interest in altering very specific brain chemicals.

-----Original Message-----From: EOHarm [mailto:EOHarm ]On Behalf Of Sent: Saturday, July 08, 2006 12:24 PMeoharm Subject: {Disarmed} Report Raises New Concerns About Antidepressants-Suicide Link

http://www.lex18.com/Global/story.asp?S=5124708 & nav=EQlsReport Raises New Concerns About Antidepressants-Suicide Link

By GardnerHealthDay Reporter

FRIDAY, July 7 (HealthDay News) -- Doctors and their patients need a more balanced picture of the risks and benefits of the popular antidepressants known as selective serotonin reuptake inhibitors (SSRIs), a new report contends.

Current practices and research methods tend to exaggerate the benefits and underestimate the risks of suicide posed by the drugs, according to an "analysis and comment" published in the July 8 issue of the British Medical Journal.

"The reason that pharmaceutical companies have been able to claim [that] the science points the other way and [health authorities] have been slow to ! take action has been because of a misguided appreciation of statistical significance" of suicide, said report author Dr. Healy, a professor of psychiatry in the North Wales Department of Psychological Medicine at Cardiff University in Bangor, Wales.

Healy, who described SSRIs as an "awfully useful group of drugs," called for reforms to the drug-approval process so health-care providers and consumers get a more complete assessment of a medication's potential benefits and risks.

"Although data submitted to the FDA show an excess of suicides with every antidepressant licensed since 1987 compared with placebo, this simple but crucial finding continues to be obscured," he said. "Companies actually manipulated the data and did it in such a way that [health authorities] were aware of it and didn't correct it."

SSRIs, the class of antidepressants that includes Prozac (fluoxetine) and Paxil (paroxetine), have been the subject of intense controversy in recent years.

In October 2004, the U.S. Food and Drug Administration directed manufacturers of SSRIs to revise their labeling to include a "black box" warning that alerts health-care providers to an increased risk of suicide and suicidal thoughts in children and teens.

In July 2005, the FDA issued a public health advisory that raised the possibility that the risk of suicidality also applied to adults taking SSRIs, after several studies pointed to that possibility.

Meanwhile, the European Medicines Agency recently ruled that children as young as 8 years old can be given Prozac. The ruling added that Prozac should only be given to children with moderate to severe depression who haven't responded to several sessions of psychotherapy. It also said the drug should only be given in small doses and must be used in tandem with counseling.

British health authorities have also declared that all antidepressants except Prozac should not be used by children or teens.

And just last month, a major new study found that SSRIs have actually saved thousands of lives by preventing suicides since they were introduced in 1988.

According to the BMJ report, GlaxoKline, which makes Paxil, recently sent a letter to doctors saying the drug caused a six-fold increase in the risk of suicidal behavior. This was in sharp contrast to a 2004 report by British health authorities, and to previous pronouncements from the company, Healy said.

Attempts by HealthDay to reach GlaxoKline for comment were unsuccessful.

Healy himself performed a meta-analysis of published trials and found that the likely risk of suicide for patients taking SSRIs compared to a placebo was 2.6 -- more than twice the risk. But new trials should be conducted to settle the issue once and for all, he said.

Healy said his main concern now is how this heightened risk could have gone unnoticed and how similar missteps can be avoided in the future.

"These are an awfully useful group of drugs, and I use them," Healy said. "The solution for me and for the people who need them is to know what the risks really are. We need to have access to the raw data and regulators do as well."

Knowing the full picture could mean the difference between life and death, Healy said.

"If we are informed what the risks are, then we don't say, 'it couldn't be the drug,' and increase the dose, which is just the wrong thing to do," he said.

More information

For more on antidepressants, visit the U.S. National Institute of Mental Health (www.nimh.nih.gov#ptdep7 ).

SOURCES: Healy, M.D., Ph.D., professor of psychiatry, North Wales Department of Psychological Medicine, Cardiff University, Bangor, Wales; July 8, 2006, British Medical Journal

Messenger with Voice.

..